On September 15, 2026, a new publication regarding teduglutide was listed in the journal Intestinal Failure (New York, N.Y.). The publication is titled "Effectiveness, safety, and quality of life outcomes of teduglutide treatment in adult patients with short bowel syndrome-associated intestinal failure: A systematic literature review of real-world studies."
This work is described as a systematic literature review, compiling real-world studies related to teduglutide treatment in adult patients with short bowel syndrome-associated intestinal failure. The title indicates that the review addresses effectiveness, safety, and quality of life outcomes as reported in existing real-world research.
No specific findings, data points, or conclusions from the review have been provided alongside this publication record. The entry serves as notice that this systematic literature review has been published and is now available through the journal Intestinal Failure.
Teduglutide carries approved regulatory status. Readers interested in further background on this compound, including its approved uses and general profile, can consult the compound overview for additional context.